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Letter to editor

Transplant Immunosuppression Management and
COVID-19
Dimitrios Giannis,1 Ioannis A. Ziogas,2 Stepan M. Esagian,3 Evangelia Matenoglou,4
Dimitrios Moris5
Dear Editor:
The novel coronavirus disease 2019 (COVID-19),
caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has become a global
health care crisis. Immunocompromised patients are
often disproportionately affected, although significant
regional differences have been observed.1,2 The Centers
for Disease Control and Prevention have listed
immunocompromised patients, including those
requiring immunosuppression after transplant, as high
risk for severe COVID-19. Treatment of other viral
infections in transplant recipients often includes a
reduction in immunosuppression; however, no
recommendations presently exist on the optimal
approach in the management of immunosuppression
in SARS-CoV-2-infected patients.
It is currently recommended that corticosteroids
are avoided for the treatment of SARS-CoV-2 in
noncritically ill patients. The effects of COVID-19 on
immunosuppressed transplant recipients are still
unclear, and reports on the role of immunosuppression and its effect on the course of the disease
remain conflicting. Hypothetically, immunosuppression increases the risk of severe infection.
However, immunosuppressant medications have
been maintained at full doses in many COVID-19infected kidney transplant recipients without the
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occurrence of any adverse events.3-6 Immunosuppression regimens may have altered the course of
COVID-19 disease in these reports. In all cases, the
authors attributed these findings to the protective
effects of immunosuppression against the overt
immune response, the so-called “cytokine storm,”
which is responsible for the development of severe
disease, such as acute respiratory distress syndrome
and multiorgan failure.7 The worse outcomes that
are observed may be attributed to the multiple
comorbidities of transplant recipients1 and not to
immunosuppression per se.
On the other hand, emerging reports have
demonstrated improved outcomes in cases with
reduced or halted immunosuppression.2,8-10 Previous
data related to the SARS-CoV-1 and MERS-CoV
outbreaks have shown that immunosuppression was
not associated with a higher risk of severe disease.11,12
These reports indicate that we are still in uncharted
waters with regard to the management of immunosuppression in SARS-CoV-2-infected transplant recipients.
Additionally, this mild initial course of illness raises
further concerns because it gives rise to "superspreading" events, namely, widespread disease transmission through infected asymptomatic individuals.
Management of drug-drug interactions between
investigational anti-SARS-CoV-2 drugs and immunosuppression may be challenging for clinicians.
Adequate immunosuppression is necessary to prevent
graft rejection, whereas critically ill SARS-CoV-2infected transplant recipients may benefit from
medications directed at limiting SARS-CoV-2
replication. Maintaining immunosuppressive drug
concentrations within the desired therapeutic range
requires a highly individualized approach that is
complicated by the pandemic context and lack of
hindsight. In addition, data from recently published
cases, describing the inpatient care of COVID-19 in
transplant recipients, differ widely in disease
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severity, time from transplant, baseline immunosuppression therapy, and the modifications made to
immunosuppression during COVID-19 treatment.13,14
Finally, there is an ethical component in the
decision-making process in all transplant patients
that transplant clinicians frequently encounter. It is
the golden rule between risk of death and risk of
graft rejection. This clinical scenario can emerge in
the era of uncertainty around optimal management of
immunosuppression and SARS-CoV-2. We advocate
for an individualized decision-making approach until
definitive guidelines are established, including
multidisciplinary discussions among clinicians, with
active and informed patient involvement, about the
risk of death on immunosuppression, the risk of graft
rejection, and the lack of preventive or definitive
therapies for COVID-19.
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